Frequency of weight and body composition increases in advanced non-small cell lung cancer patients during first line therapy.

Autor: Bonomi P; Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL, USA., Moudgalya H; Department of Anatomy and Cell Biology, Rush University Medical Center, Chicago, IL, USA., Gomez SL; Department of Clinical Nutrition, Rush University Medical Center, Chicago, IL, USA., Shah P; Department of Radiology, Rush University Medical Center, Chicago, IL, USA., Basu S; Biostatistics, School of Public Health, University of Illinois Chicago, Chicago, IL, USA., Batus M; Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL, USA., Martinka LB; Department of Anatomy and Cell Biology, Rush University Medical Center, Chicago, IL, USA., Abdelkader A; Department of Anatomy and Cell Biology, Rush University Medical Center, Chicago, IL, USA., Tzameli I; Internal Medicine Research Unit, Pfizer Inc., Cambridge, MA, USA., Cobain S; Global Biometrics and Data Management, Pfizer R&D UK Ltd, Sandwich, UK., Collins S; Global Biometrics and Data Management, Pfizer R&D UK Ltd, Sandwich, UK., Keliher EJ; Early Clinical Development, Pfizer Inc., Cambridge, MA, USA., Breen DM; Internal Medicine Research Unit, Pfizer Inc., Cambridge, MA, USA., Calle RA; Internal Medicine Research Unit, Pfizer Inc., Cambridge, MA, USA., Fidler MJ; Division of Hematology/Oncology, Rush University Medical Center, Chicago, IL, USA., Borgia JA; Department of Anatomy and Cell Biology, Rush University Medical Center, Chicago, IL, USA.; Department of Pathology, Rush University Medical Center, Chicago, IL, USA.
Jazyk: angličtina
Zdroj: Journal of cachexia, sarcopenia and muscle [J Cachexia Sarcopenia Muscle] 2024 Sep 17. Date of Electronic Publication: 2024 Sep 17.
DOI: 10.1002/jcsm.13534
Abstrakt: Background: The primary objective of this study was to assess the frequency of body composition increases and their relationships to changes in body weight in two cohorts of real world, treatment-naïve, advanced non-small cell lung cancer (NSCLC) patients. One cohort received the current standard of care (CSOC), which consisted of immunotherapy and newer chemotherapy regimens, and the other cohort was treated with the former standard of care (FSOC), consisting only of older platinum-containing regimens.
Methods: CSOC (n = 106) and FSOC (n = 88) cohorts of advanced NSCLC patients were included in this study. Weights were collected at each clinical visit, and body composition analysis from routine chest computed tomography via automated segmentation software assessed at baseline and at 6 and 12 weeks. Standard statistical methods were used to calculate relationships between changes in weight and in body composition.
Results: The CSOC cohort contained 106 stage IV NSCLC patients treated between 16/12/2014 and 22/10/2020 while the FSOC cohort contained 88 stage III/IV NSCLC patients treated between 16/6/2006 and 18/11/2014. While each cohort exhibited decreases in median weight, body mass index (BMI), mean skeletal muscle index (SMI) and subcutaneous adipose tissue index (SATI) at the 6 and 12 week time points, a subset of patients experienced increases in these parameters. Using a threshold of ≥2.5% increase for weight, BMI, SMI, and SATI at the 12 week time point, both cohorts showed similar (20.5% and 27.3%) increases in these parameters. With a cut point of ≥5% increase at 12 weeks follow-up, 8.0% to 25.0% of the patients gained ≥5% in weight, BMI, SMI and SATI. Comparing these results in each cohort showed no significant differences. Pearson coefficients for weight change related to changes in SMI and SATI at 6 and 12 weeks ranged from 0.31 to 0.58 with all P values <0.02. Pearson coefficients for weight change at 12 weeks related to changes in VATI and IMATI ranged from 0.26 to 0.47 with all P values <0.05. Comparison of Pearson coefficients for each cohort showed no significant differences.
Conclusions: Although decreases in median weight, BMI, SMI and SATI were observed in both cohorts, similar percentage of patients in each cohort experienced increases in these parameters. These findings, plus the positive correlations between longitudinal measurements of weight, muscle mass and adipose tissue, indicate that weight gain in these patients involves increases in both muscle mass and adipose tissue. Upon validation, these findings could have implications for clinical trial design and for translational research in cancer cachexia.
(© 2024 The Author(s). Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: